Despite the declining top line, shares of Moderna (MRNA) continue to soar thanks to its encouraging pipeline updates and potential product launches over the next few years. The company boasts of a pipeline of more than 40 mRNA-based investigational candidates across different stages of development, targeting multiple indications, including cancer and cardiovascular. Being one of the handful of makers of a COVID-19 vaccine, Moderna reaped the benefits of the COVID-19 pandemic, allowing it to strengthen its c ...

It's not uncommon for companies to face regulatory setbacks -- and It's not the end of the world. Biotech investors aren't fond of regulatory delays. Brand-new products have a limited shelf life before they run out of patent protection. The less time they spend on the market, the less they will generate in sales. But in this The past two-and-a-half years have been rough for Moderna (MRNA 1.58%). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche t ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna (MRNA) and Pfizer (PFE) to set up a possible vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans. These reports came to light after the discovery of two cases of H5N1 virus in dairy farm workers in Texas and Michigan this year. Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5 ...

Moderna (NASDAQ:MRNA) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology firm. Indeed, the company has climbed 44% so far this year as one of the big winners of 2024's bull market. What's pushing MRNA stock up lately? Well, it appears the company is benefitting primarily from three main drivers: MRNA Stock Climbs Despite Mixed Analyst Ratings While Moderna has plenty of potential growth avenues, some believe MRNA stock may ...

After two years in the doldrums, the stock is soaring. Moderna (MRNA 1.90%) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save crucial time in the laboratory. For example, Moderna uses AI to produce mRNAs for researchers to work with, so they no longer have to create mRNA manually to run experiments. And last year, it signed a deal with International Business Machines to use its AI and quan ...

Moderna's RSV candidate First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe for certain groups like elderly people or infants. Moderna is seeking approval for its vaccine in people over age 60 in various countries around the world, including the U.S. Last year, regulators approved two other RSV vaccines -- from GSK and Pfizer -- so Moderna isn't the only player in this field. But there's room for more than one, and Moderna may even ex ...

Shares of Moderna, Inc. (MRNA) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345. Moderna has developed mRNA-1345 for use in older adults (aged 60 years and above). The regulatory body notified the company that due to administrative constraints, it would not be able to complete the review of the biologics license application (BLA) for mRNA-1345 by the Prescription Drug User Fee Act date o ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this biotechnology company have returned +11.6%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has gained 0.8%. The key question now is: What could be the stock's future direction ...

This team-up is more than a PR stunt, but it might not be revolutionary.Moderna (MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors. If the lofty claims made by others in the biotech industry are true, the company could see a smattering of benefits that ultimately enable it to capture more earnings. And, at a time when its coronavirus vaccine revenue is no longer enough to make t ...

Key TakeawaysModerna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine.The biotech reported it was advised by regulators that their review wouldn't be completed until the end of the month, whereas previously it was expected on May 12.Moderna is moving to produce vaccines for other diseases now that demand for its COVID-19 shot has declined with the pandemic over. Moderna (MRNA) shares lost ground in intraday trading Friday as the ...